Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study

International Journal of Cancer, 04/24/2012

The outcome of the phase II trial warrants new studies on the use of low–dose cyclophosphamide to potentiate the immunogenicity of the p53–SLP vaccine or other antitumor vaccines.

Print Article Summary Cat 2 CME Report